Sandeep Menon - 06 Apr 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Chief R&D Officer
Issuer ticker: BCRX
Reported as of: 06 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Apr 2026, 16:24:44 UTC
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Sandeep Menon filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 07 Apr 2026.

Key facts

This page summarizes Sandeep Menon's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Apr 2026, 16:24.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002123967 Primary reporting owner

Menon Sandeep

Relationship: Chief R&D Officer
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 07 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value
Shares: +205,150
Change %
Price: $0.000000^*
Shares after: 205,150
Date: 06 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Emp. Stock Option (Right to Buy)

Award

Transaction value
Shares: +441,350
Change %
Price: $0.000000^*
Shares after: 441,350
Date: 06 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 441,350
Exercise price: $9.47
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Footnote F2

Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.